埃万妥单抗新增适应症获批，用于晚期非小细胞肺癌一线联合治疗

Core Viewpoint - Johnson & Johnson's drug Evusheld (Evusheld) has been approved by the National Medical Products Administration for use in combination with Lenvatinib (Lenvatinib) as a first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying EGFR 19 exon deletions or L858R substitution mutations [1][2]. Group 1: Drug Approval and Indications - Evusheld has received approval for its third indication in lung cancer in China, previously being approved for patients with EGFR 20 exon insertion mutations and for those with classic EGFR mutations who progressed during or after EGFR TKI treatment [2]. Group 2: Lung Cancer Statistics and Treatment Challenges - Lung cancer is the most common malignant tumor in China, with incidence and mortality rates ranking first among malignant tumors, where non-small cell lung cancer accounts for 80%-85% of total lung cancer cases [1]. - Among patients with advanced non-small cell lung cancer with EGFR mutations, 25%-39% are unable to continue second-line treatment due to disease progression [1]. - The five-year survival rate for patients with advanced non-small cell lung cancer receiving EGFR TKI treatment is less than 20% [1]. Group 3: Mechanism and Benefits of Evusheld - The combination of Evusheld and Lenvatinib offers a new treatment option for patients with advanced non-small cell lung cancer, directly inhibiting tumor signaling pathways by blocking ligand binding and receptor degradation, while also providing immune cell-directed activity for more sustained clinical benefits [1].